A. Necchi Et Al. , "Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial," The Lancet Oncology , vol.25, no.6, pp.720-730, 2024
Necchi, A. Et Al. 2024. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. The Lancet Oncology , vol.25, no.6 , 720-730.
Necchi, A., Roumiguié, M., Kamat, A. M., Shore, N. D., Boormans, J. L., ESEN, A. A., ... Lebret, T.(2024). Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. The Lancet Oncology , vol.25, no.6, 720-730.
Necchi, Andrea Et Al. "Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial," The Lancet Oncology , vol.25, no.6, 720-730, 2024
Necchi, Andrea Et Al. "Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial." The Lancet Oncology , vol.25, no.6, pp.720-730, 2024
Necchi, A. Et Al. (2024) . "Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial." The Lancet Oncology , vol.25, no.6, pp.720-730.
@article{article, author={Andrea Necchi Et Al. }, title={Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial}, journal={The Lancet Oncology}, year=2024, pages={720-730} }